We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

This study has been withdrawn prior to enrollment.
(Study was pending major changes and was on hold, pending activation; administratively withdrawn; will be submitted as a new protocol if study is revised.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01600807
First Posted: May 17, 2012
Last Update Posted: June 26, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Brian Wolpin, MD, MPH, Dana-Farber Cancer Institute
  Purpose

OSI-906 is a new drug that may stop cancer cells from growing abnormally. This drug has been used in other research studies and information from those suggests that OSI-906 may help block cell receptors involved in tumor growth.

Gemcitabine and erlotinib are used as standard treatment for pancreatic cancer. In this research study, the investigators are looking for the highest dose of OSI-906 that can be given safely in combination with gemcitabine and erlotinib. This dose will then be given together with gemcitabine and erlotinib to a further group of patients with pancreatic cancer.


Condition Intervention Phase
Pancreatic Cancer, Metastatic Drug: Gemcitabine, Erlotinib, OSI-906 Drug: Gemcitabine, Erlotinib Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Trial of OSI-906 in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Ductal Adenocarcinoma of the Pancreas

Resource links provided by NLM:


Further study details as provided by Brian Wolpin, MD, MPH, Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • Number of patients with adverse events as a measure of safety and tolerability [ Time Frame: 1 years ]
    Phase I study to assess the safety, tolerability and maximally tolerated dose (MTD) of OSI-906 administered in combination with gemcitabine and erlotinib is patients with metastatic pancreatic ductal adenocarcinoma

  • Survival among patients receiving gemcitabine + erlotinib versus gemcitabine + erlotinib + OSI-906 [ Time Frame: 2 years ]
    Phase II trial to assess overall survival associated with OSI-906, gemcitabine and erlotinib compared with gemcitabine and erlotinib alone in patients with previous untreated metastatic pancreatic ductal adenocarcinoma


Secondary Outcome Measures:
  • Progression-free survival among patients receiving gemcitabine + erlotinib vs. gemcitabine + erlotinib + OSI-906 [ Time Frame: 2 years ]
    To assess progression-free survival associated with OSI-906, gemcitabine and erlotinib compared to gemcitabine and erlotinib alone in patients with previously untreated metastatic pancreatic ductal adenocarcinoma

  • Tumor response rate among patients receiving gemcitabine + erlotinib versus gemcitabine + erlotinib + OSI-906 [ Time Frame: 2 years ]
    To assess tumor response rate associated with OSI-906, gemcitabine and erlotinib compared to gemcitabine and erlotinib alone in patients with previously untreated metastatic pancreatic ductal adenocarcinoma


Enrollment: 0
Arms Assigned Interventions
Experimental: Gemcitabine, Erlotinib, OSI-906
Experimental treatment arm
Drug: Gemcitabine, Erlotinib, OSI-906
Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID
Other Names:
  • Gemzaar
  • Tarceva
Active Comparator: Gemcitabine, Erlotinib
Standard treatment arm
Drug: Gemcitabine, Erlotinib
Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
Other Names:
  • Gemzaar
  • Tarceva

Detailed Description:

This study will be conducted in two parts: a phase I study and a phase II study. In both instances, a treatment cycle is 28 days (4 weeks). Subjects will take OSI-906 by mouth, twice a day, every day. Subjects will receive gemcitabine through an IV in clinic over 30 minutes on days 1, 8 and 15 of each 28-day cycle. Subjects will take erlotinib by mouth, once a day, every day.

At every visit subjects will have a physical exam and blood tests. An EKG will be done on days 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. A CT scan will be done every 2 cycles (8 weeks).

Subjects will complete a daily drug diary and perform glucose monitoring (finger stick) once daily at home.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Metastatic pancreatic ductal adenocarcinoma
  • Measurable disease
  • Life expectancy > 12 weeks
  • Normal organ and marrow function
  • Fasting blood glucose </= 150 mg/dL
  • Able to swallow pills

Exclusion Criteria:

  • Prior chemotherapy or radiotherapy for treatment of pancreatic cancer
  • Receiving any other experimental agent
  • Known brain metastases
  • History of allergic reaction attributed to compounds of similar chemical or biologic composition to gemcitabine, erlotinib, or OSI-906
  • Impairment of gastrointestinal function or gastrointestinal disease (e.g., ulcerative disease, uncontrolled nausea, vomiting, or diarrhea)
  • Use of enzyme-inducing anti-epileptic drugs
  • Diabetes mellitus which requires the use of exogenous insulin for glucose control
  • Major surgery within 4 weeks of the start of study treatment
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Use of strong or moderate CYP1A2 inhibitors/inducers
  • Pregnant or breast feeding
  • History of a different malignancy unless disease-free for at least 3 years
  • HIV positive
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01600807


Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02214
Sponsors and Collaborators
Dana-Farber Cancer Institute
Investigators
Principal Investigator: Brian Wolpin, MD, MPH Dana-Farber Cancer Institute
  More Information

Responsible Party: Brian Wolpin, MD, MPH, Overall PI, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT01600807     History of Changes
Other Study ID Numbers: 11-148
First Submitted: August 8, 2011
First Posted: May 17, 2012
Last Update Posted: June 26, 2013
Last Verified: June 2013

Keywords provided by Brian Wolpin, MD, MPH, Dana-Farber Cancer Institute:
Metastatic
Pancreas
Cancer
Adenocarcinoma

Additional relevant MeSH terms:
Adenocarcinoma
Pancreatic Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Gemcitabine
Erlotinib Hydrochloride
Pancrelipase
Pancreatin
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Protein Kinase Inhibitors
Gastrointestinal Agents